BAYER AG
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components
- Conditions
- Contraception
- Interventions
- Drug: BAY98-7443Drug: Levonogestrel (Skyla, BAY86-5028)
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 177
- Registration Number
- NCT03562624
- Locations
- π©πͺ
Frauenarztpraxis Dr. Wetzel, Blankenburg, Sachsen-Anhalt, Germany
π©πͺNuvisan GmbH, Neu-Ulm, Bayern, Germany
π¬π§PAREXEL International Early Phase Clinical Unit (London), Harrow, United Kingdom
An Evaluation of a Gender Specific Insole to Provide Relief From Knee Pain Due to Osteoarthritis or General Anterior Knee Pain in Male Subjects When Used in Foot Wear Over a Period of Four Weeks
- Conditions
- Osteoarthritis, Knee
- Interventions
- Device: BPI 1000013 (Dr Scholls Insole)
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 89
- Registration Number
- NCT03556787
- Locations
- πΊπΈ
Focus & Testing, Inc., Calabasas, California, United States
πΊπΈThe Wolf Group, Cincinnati, Ohio, United States
Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF
- Conditions
- Chronic Heart Failure With Preserved Ejection Fraction
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 789
- Registration Number
- NCT03547583
- Locations
- πΊπΈ
Capitol Interventional Cardiology, Carmichael, California, United States
πΊπΈCardiovascular and Vein Center of Florida, Bradenton, Florida, United States
πΊπΈFox Valley Clinical Research Center, LLC, Aurora, Illinois, United States
Maintenance Treatment of Renal Anemia in Dialysis Subjects
- Conditions
- Renal Insufficiency, ChronicAnemia
- Interventions
- Drug: Molidustat (BAY85-3934)Drug: Darbepoetin alfaDrug: Placebo of Molidustat (BAY85-3934)Drug: Placebo of Darbepoetin alfa
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 229
- Registration Number
- NCT03543657
- Locations
- π―π΅
Chibune Clinic, Osaka, Japan
π―π΅Maruko Central Hospital, Ueda, Nagano, Japan
π―π΅Houshikai Kano hospital, Kasuya-gun, Fukuoka, Japan
BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: PlaceboDrug: BAY1830839
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 64
- Registration Number
- NCT03540615
- Locations
- π©πͺ
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 59
- Registration Number
- NCT03535168
- Locations
- π³π±
Catharina Ziekenhuis, Eindhoven, Noord-Brabant, Netherlands
π³π±Isala, Zwolle, Netherlands
π¬π§Birmingham Heartlands Hospital, Birmingham, West Midlands, United Kingdom
An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies
- Conditions
- Macular Degeneration
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1000
- Registration Number
- NCT03521895
- Locations
- π©πͺ
Many locations, Multiple Locations, Germany
Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
- Conditions
- Advanced or Metastatic Solid Tumor
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT03517956
- Locations
- πΊπΈ
University of Maryland, Baltimore, Maryland, United States
πΈπ¬National University Hospital, Singapore, Singapore
πͺπΈCiutat SanitΓ ria i Universitaria de la Vall d'Hebron, Barcelona, Spain
A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects
- Conditions
- Clinical Pharmacology
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 52
- Registration Number
- NCT03517930
- Locations
- πΊπΈ
Frontage Clinical Services, Secaucus, New Jersey, United States
A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects
- Conditions
- Clinical Pharmacology
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 29
- Registration Number
- NCT03517943
- Locations
- πΊπΈ
Frontage Clinical Services, Secaucus, New Jersey, United States